Related Experiment Videos
[Medical treatment of fragile X syndrome]
J Artigas-Pallarés1, C Brun-Gasca
1Unidad de Neuropediatría, Hospital de Sabadell, Corporació Sanitària Parc Tauli, Sabadell, Barcelona, Spain. jartigas@cspt.es
Abstract:
There is still no medication for fragile X syndrome (FXS) which acts directly on the genetic mechanisms or on the immediate result of the genetic defect. However, behavioral and cognitive manifestations can be approached from both the psychological/educational and pharmacological sides. Both approaches are not mutually exclusive but are complementary and synergic. There are currently potent drugs which can improve important symptoms of the FXS, behavioral disorders, hyperactivity, attention deficit, obsessive disorders and anxiety. Pharmacological treatment can be useful: CNS stimulants, clonidine, folic acid, serotonin reuptake inhibitors, and atypical antipsychotics. Pharmacological treatment of epilepsy is needed whenever epilepsy occurs. There is no specific antiepileptic for FXS, so action must be taken with the most efficient antiepileptic according to the crisis type, evaluating tolerance and possible effects on behavior. Insomnia is also of interest in children with FXS. In this case the use of melatonin can be of great help.
Insights
Currently, no direct genetic treatments exist for fragile X syndrome (FXS). However, pharmacological interventions can effectively manage symptoms like behavioral disorders and anxiety, complementing other therapies.
Area of Science:
- Neuroscience
- Genetics
- Pharmacology
Context:
- Fragile X syndrome (FXS) lacks direct genetic therapies.
- Behavioral and cognitive symptoms significantly impact quality of life.
- Current management relies on symptomatic and supportive approaches.
Purpose:
- To review current pharmacological strategies for managing fragile X syndrome (FXS) symptoms.
- To highlight the complementary role of pharmacotherapy alongside psychological and educational interventions.
- To discuss specific drug classes and their efficacy in addressing FXS manifestations.
Summary:
- While no cure exists for FXS, medications can target key symptoms.
- Effective pharmacological options include CNS stimulants, clonidine, folic acid, SSRIs, and atypical antipsychotics.
- Epilepsy and insomnia associated with FXS require specific, individualized pharmacological management.
Impact:
- Pharmacological treatments offer significant improvements in behavioral and cognitive symptoms of FXS.
- Integrated treatment plans combining medication with behavioral therapies enhance patient outcomes.
- Further research into targeted therapies for FXS is warranted.